Immunotherapy and cancer vaccines

Treatment of cancer is a fundamental challenge and there is a continuous need for new inventions that are able to cure or prolong survival of patients. Fortunately, the recent years has illustrated a large potential of therapeutic success imposed by modifying the immune system in favor of cancer cell detection and destruction. The CBIO group runs a series of projects, wherein immunomodulation is induced using advanced nanotechnologies to stimulate a strong anti-cancer response. These technologies include: (i) enzyme-sensitive liposomes (lipid nanoparticles) capable of stimulating the release of tumor antigens and a downstream immune response, (ii) carbohydrate formulations enabling localized and sustained release of therapeutic compounds, pro-inflammatory cytokines, or tumor antigens, (iii) lipid micelle formulations that deliver immune-stimulating compounds to enforce anti-tumor immune responses, and (iv) various nanomaterials capable of improving the immune cell’s capacity for cancer cell destruction in adoptive cell transfer and other cell-based therapies. In addition to the expertise in chemical synthesis and formulation required to develop these technologies, the group has scientists with strong expertise in immunology as well as access to state-of-the-art instrumentation, including; flow cytometers, cell sorters, pre-clinical cancer models, and bioimaging technologies (see Functional bioimaging and tracer development). This allows for detailed studies of how the newly developed immunotherapies interact with biological systems.

Contact

Anders Elias Hansen
Senior Researcher
DTU Health Tech
+45 45 25 81 39

Contact

Thomas Lars Andresen
Professor
DTU Health Tech
+45 25 37 44 86

Contact

Jonas Rosager Henriksen
Head of Section, Associate Professor
DTU Health Tech
+45 40 58 28 66

Contact

Gael Clergeaud Veiga
Researcher
DTU Health Tech
+45 45 25 81 35

Contact

Carl Fredrik Melander
Researcher
DTU Health Tech
+45 45 25 81 32